首次授予相关事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性、完整性承担法律责任。 重要内容提示（简称同正文） ●首次授予调整：建议承授人由 201 名调整为 195 名、所涉 H 股受限制股份 单位数量由 10,696,400 份调整为 10,589,500 份 ●首次授予日：2025 年 11 月 4 日 证券代码：600196 证券简称：复星医药 公告编号：临 2025-172 上海复星医药（集团）股份有限公司 关于 2025 年 H 股受限制股份单位计划 ●首次授予 H 股受限制股份单位数量：10,589,500 份 一、2025 年 H 股受限制股份单位计划已履行的决策程序和信息披露情况 （一）2025 年 8 月 22 日，上海复星医药（集团）股份有限公司（以下简称 "本公司"或"复星医药"）第十届董事会第七次会议审议通过关于《上海复星 医药（集团）股份有限公司 2025 年 H 股受限制股份单位计划（草案）》（以下简 称"2025 年 H 股受限制股份单位计划"或"本次激励计划"）、根据该计划向合 资格雇员作出首次授予的议案 ...

表决结果：同意 6 票，反对 0 票，弃权 0 票。 本议案在提交董事会审议前，已经董事会薪酬与考核委员会审核通过。 详情请见同日发布之《关于 2025 年 A 股股票期权激励计划首次授予调整及 证券代码：600196 证券简称：复星医药 公告编号：临 2025-170 上海复星医药（集团）股份有限公司 第十届董事会第十四次会议（临时会议）决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海复星医药（集团）股份有限公司（以下简称"本公司"）第十届董事会 第十四次会议（临时会议）于 2025 年 11 月 4 日召开，全体董事以通讯方式出席 了会议。本次会议的召开符合《中华人民共和国公司法》、其他有关法律法规和 《上海复星医药（集团）股份有限公司章程》的规定。会议审议并达成如下决议： 一、审议通过关于 2025 年 A 股股票期权激励计划首次授予相关事项的议案。 1、根据本公司 2025 年第一次临时股东会（以下简称"股东会"）已审议通 过之《上海复星医药（集团）股份有限公司 2025 年 A 股股票期权激励计划》（以 ...

上海复星医药（集团）股份有限公司 董事会薪酬与考核委员会 关于 2025 年 A 股股票期权激励计划首次授予相关事项的核查意见 上海复星医药（集团）股份有限公司（以下简称"本公司"）董事会薪酬与 考核委员会依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》 （以下简称"《管理办法》"）等相关法律法规及规范性文件和《上海复星医药 （集团）股份有限公司章程》（以下简称"《公司章程》"）的有关规定，对《上 海复星医药（集团）股份有限公司 2025 年 A 股股票期权激励计划》（以下简称 "2025 年 A 股股票期权计划"或"本次激励计划"）及相关资料进行核查核实后， 发表如下核查意见： 本次激励计划首次授予的激励对象包括本公司现任执行董事、职工董事、高 级管理人员，本集团（即本公司及控股子公司/单位，下同）现任中层管理人员、 核心技术（业务）人员，以及其他经董事会认定的对本集团整体业绩和持续发展 有直接影响的核心骨干人员；首次授予激励对象符合《公司法》《证券法》等法 1 由于部分首次授予拟激励对象不再属于本次激励计划激励对象范 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海復星醫藥(集團)股份有限公司 ( 於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02196 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 540,971,500 | | 10,969,000 | | 551,940,500 | | 增加 / 減少 (-) | | | | 0 | | 0 | | | | 本月底結存 | | | | 540,971,500 | | 10,969,000 | | 55 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海復星醫藥(集團)股份有限公司 ( 於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02196 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 551,940,500 | RMB | | 1 RMB | | 551,940,500 | | 增加 / 減少 (-) | | | | 0 | | RMB | | 0 | | 本月底結存 | | | 551,940,500 | RMB | | 1 RMB | | 551,940,500 ...

Group 1 - Taifu Pump Industry has terminated the acquisition of 51% equity in Nanyang Huacheng [1] - Shareholder Fosun Pharma of Shanhe Pharmaceutical Auxiliary plans to reduce its stake by no more than 3% [1] - Several convertible bonds including Anji Convertible Bond, Longda Convertible Bond, and Oujing Convertible Bond will not undergo forced redemption [1][2] Group 2 - The following convertible bonds will not be adjusted: Oujing Convertible Bond, Longda Convertible Bond, and Tong 22 Convertible Bond [2] - New shares from Danna Biotechnology will be listed on the Beijing Stock Exchange [1] - North Mining Testing is also set to issue new shares on the Beijing Stock Exchange [1]

Core Viewpoint - The technology sector experienced significant declines, prompting a structural shift in market funds towards the innovative drug sector, which saw notable gains on the same day [1][3]. Group 1: Market Performance - The innovative drug sector rose by 3.91% amidst a downturn in the technology sector, successfully breaking through the 20-day moving average with increased trading volume, signaling positive market sentiment [3]. - The innovative drug sector had been in a downward trend since August but began to stabilize and form a bottom pattern in October [3]. Group 2: Multiple Sclerosis (MS) Market - The global market for MS drugs is projected to reach approximately $18.5 billion in 2024, with a significant portion of sales coming from third-generation products, particularly CD20 monoclonal antibodies [6]. - CD20 monoclonal antibodies are expected to account for over 60% of the MS drug sales in 2024, with the drug Ocrelizumab projected to generate sales of 7.64 billion yuan, reflecting a year-on-year growth of 7.4% [6]. Group 3: Chemical Pharmaceutical Industry - The global chemical pharmaceutical market grew from $1,038 billion in 2019 to $1,128 billion in 2023, with expectations to reach $1,156 billion in 2024 [10]. - In China, the chemical pharmaceutical market size was 883.9 billion yuan in 2022, with a year-on-year growth of 4.4%, projected to increase to 945 billion yuan by 2024 [10]. Group 4: Innovative Drug Sector Performance - In the first half of 2025, 21 A-share innovative drug companies reported revenues of 28.69 billion yuan, a year-on-year increase of 42%, while net losses narrowed significantly [11]. - The second quarter of 2025 saw these companies achieve revenues of 15.34 billion yuan, a 39% increase year-on-year, with net losses reduced by 97% [11][12]. Group 5: Future Outlook - Continued policy support for innovative drugs is expected to enhance performance, with an increase in product launches anticipated to drive revenue growth [15]. - The active business development (BD) transactions in the innovative drug sector in the first half of 2025 are expected to bolster the apparent performance of related companies [15].

Core Viewpoint - On October 31, six A-share listed companies disclosed their share reduction plans, with no companies announcing share increases on the same day [1]. Summary by Category Share Reduction Plans - Anke Zhidian: Shareholder Chen Xiaohui plans to reduce holdings by no more than 1% of the company's shares [2] - Shanhe Yaofu: Shareholder Fosun Pharma intends to reduce holdings by no more than 3.00% of shares [2] - Tuosida: Director and executive Huang Daibo plans to reduce holdings by no more than 0.95% of shares [2] - Saiwu Technology: Shareholder Dongyun Chuangtou plans to reduce holdings by no more than 1% of shares [2] - Dadi Xiong: Some directors and executives plan to collectively reduce holdings by no more than 0.75% of the company's shares [2] - Kanglongda: Shareholder Juyin Fund intends to reduce holdings by no more than 3.00% of shares [2]

Core Viewpoint - Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. plans to reduce its stake in Shanhe Pharmaceutical (300452) by up to 6.9787 million shares, representing no more than 3% of the company's total share capital within 90 days after a 15 trading day period from the announcement date [1] Group 1 - Fosun Pharmaceutical currently holds 21.6453 million shares in Shanhe Pharmaceutical, accounting for 9.23% of the company's total share capital [1]

Group 1 - Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. plans to reduce its stake in Shanhe Pharmaceutical Excipients Co., Ltd. by up to approximately 6.98 million shares, which is no more than 3% of the total share capital after deducting repurchased shares [1] - The reduction will occur within 90 days after a 15 trading day period following the announcement [1] - Shanhe Pharmaceutical Excipients' revenue composition for the year 2024 is expected to be 100% from the pharmaceutical manufacturing industry [1] Group 2 - As of the report, Shanhe Pharmaceutical Excipients has a market capitalization of 3.3 billion yuan [2]